Objectives: Children and adults are likely to be among the casualties in a civilian nerve agent exposure. This study evaluated the efficacy of valnoctamide (racemic-VCD), sec-butylpropylacetamide (racemic-SPD), and phenobarbital for stopping nerve agent seizures in both immature and adult rats. Methods: Female and male postnatal day (PND) 21, 28, and 70 (adult) rats, previously implanted with electroencephalography (EEG) electrodes were exposed to seizure-inducing doses of the nerve agents sarin or VX and EEG was recorded continuously. Five minutes after seizure onset, animals were treated with SPD, VCD, or phenobarbital. The up-down method was used over successive animals to determine the anticonvulsant median effective dose (ED 50 ) of the drugs. Results: SPD-ED 50 values in the VX model were the following: PND21, 53 mg/ kg (male) and 48 mg/kg (female); PND28, 108 mg/kg (male) and 43 mg/kg (female); and PND70, 101 mg/kg (male) and 40 mg/kg (female). SPD-ED 50 values in the sarin model were the following: PND21, 44 mg/kg (male) and 28 mg/kg (female); PND28, 79 mg/kg (male) and 34 mg/kg (female); and PND70, 53 mg/ kg (male) and 53 mg/kg (female). VCD-ED 50 values in the VX model were the following: PND21, 34 mg/kg (male) and 43 mg/kg (female); PND28, 165 mg/kg (male) and 59 mg/kg (female); and PND70, 87 mg/kg (male) and 91 mg/kg (female). VCD-ED 50 values in the sarin model were the following: PND21, 45 mg/ kg (male), 48 mg/kg (female); PND28, 152 mg/kg (male) 79 mg/kg (female); and PND70, 97 mg/kg (male) 79 mg/kg (female). Phenobarbital-ED 50 values in the VX model were the following: PND21, 43 mg/kg (male) and 18 mg/kg (female); PND28, 48 mg/kg (male) and 97 mg/kg (female). Phenobarbital-ED 50 values in the sarin model were the following: PND21, 32 mg/kg (male) and 32 mg/kg (female); PND28, 58 mg/kg (male) and 97 mg/kg (female); and PND70, 65 mg/kg (female).
| INTRODUCTION
One of the most severe conditions of epilepsy is status epilepticus (SE). This is a medical emergency condition that may lead to permanent brain damage or even death.
1,2 Nerve agents elicit prolonged seizures that have all the behavioral and electrographic characteristics of SE. 3 The most widely used therapy for early treatment of SE are the benzodiazepines. 4 More common antiepileptic drugs (AEDs), such as valproic acid (VPA), phenytoin, or levetiracetam, are considered second-line therapy for established SE, but are all ineffective in stopping soman-induced SE. 1, 5 However, in various animal models of SE as well as clinically, it has been shown that the longer a seizure progresses before benzodiazepine treatment, the less responsive seizures become to benzodiazepines and other AEDs. 3, 6 Racemic-valnoctamide (VCD) and racemic-sec-butylpropylacetamide (SPD) have proven in pilocarpine-and soman-induced SE animal models to be active in benzodiazepine-resistant SE models when given 30 and even 60 minutes after seizure onset. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] For more severe cases, anesthetic agents like propofol and pentobarbital are used as third-line therapy. First-and second-line therapies often do not suppress electrographic SE, and both second-and third-line therapies must be administered in a medical treatment facility. 2, 5 Therefore, there is currently a substantial need to develop novel therapies to treat refractory SE.
Valnoctamide is a central nervous system (CNS)-active chiral constitutional isomer of VPD, the corresponding amide of VPA, and SPD is a one-carbon homologue of VCD with an additional methyl group. In contrast to VPD, which is a prodrug of VPA, both VCD and SPD act as drugs on their own with minimal biotransformation to their corresponding acids. Both racemic-SPD and racemic-VCD (Figure 1 ) possess unique and broad-spectrum antiepileptic profiles in a wide array of anticonvulsant models; these profiles are superior to that of VPA, with median effective dose (ED 50 ) values 3-20 times smaller than those of VPA. 7, 8, 12 SPD and VCD possess 2 stereogenic carbons in their chemical structure and exhibit stereoselective pharmacokinetics in humans and dogs (VCD) and rats (VCD and SPD). 7, 8, [13] [14] [15] Some AEDs exhibit qualitative or quantitative changes of their anticonvulsant activity during postnatal development. [17] [18] [19] [20] [21] [22] In addition, children are likely to be among the casualties in a civilian nerve agent exposure, as recent events in Syria have demonstrated (http://www.who. int/mediacentre/news/statements/2018/chemical-attackssyria/en). Therefore, the efficacy of anticonvulsants used to treat nerve agent-induced SE needs to be studied in both immature and adult subjects. Consequently, the aims of the current study were to determine if racemic-SPD, racemic-VCD, and phenobarbital, three drugs that enhance γ-aminobutyric acid (GABA) ergic signaling, 11 could provide anticonvulsant protection against seizures elicited by the nerve agents sarin and VX in both immature and adult animal models, and to investigate if the efficacy of these compounds changes over different developmental ages. Sarin and VX were chosen as the challenge nerve agents because they have been used most frequently in terrorist attacks (Japan nerve agent attacks by the Aum Shinrikyo cult; the assassination of Kim Jong Nam and; and in the recent civil conflict in Syria). The recently developed model of nerve agent-induced SE in both immature and adult rats 22, 23 was used to evaluate the anticonvulsant efficacy of these drugs.
| METHODS

| Chemicals and reagents
All the solvents were of analytical grade or high-performance liquid chromatography (HPLC) grade and were
Key Points
• Anticonvulsant-ED 50 values varied with age and sex • SPD, VCD, and phenobarbital are more effective in PND21 rats, requiring that younger animals receive lower doses of the drugs • Phenobarbital has been effective in pediatric rats but its ED 50 values could not be determined in adult rats due to higher doses required that were accompanied by toxicity • SPD and VCD have now displayed excellent anticonvulsant activity in multiple rat models of SE purchased from J.T. Baker (The Netherlands). SPD and VCD were synthesized according to previously described syntheses. 24 The chemical structures of the synthesized SPD and VCD and their purity were assessed by proton nuclear magnetic resonance (H-NMR), gas chromatography-mass spectrum (GC-MS), and elemental analysis, 14, 24 and the results obtained were as follows. 143.1310; found: 143.1322, indicating 99% purity. Sarin and VX (>97% pure by phosphorus NMR analysis) came from US Army Medical Research Institute of Chemical Defense stocks; aliquots were kept at −80°C, thawed on the day of use, and maintained on ice during the study. Pralidoxime Cl (2PAM; 100% purity) was purchased from Science Labs; atropine sulfate for injection (USP) was purchased from Sparhawk Labs and methyl atropine nitrate (pharmacopeial purity of 98%) was purchased from Sigma-Aldrich phenobarbital sodium for injection (USP) was purchased from West-Ward.
| Animal studies
Female and male postnatal day (PND) 21, 28, and 70 adult control rats were surgically implanted with stainless steel electroencephalography (EEG) screw electrodes and headpieces (Plastics One) 2 days (PND21/28 rats) or 7 days (PND70 rats) before study. These PND ages represent 3-to 6-year-old, 8-to 10-year-old, and 15-to 18-year-old human equivalent ages, respectively, depending on the method used to calculate equivalence. 25 Animals of each sex in each age group were randomly assigned to an agent challenge by coin flip.
On the day of the study, the animals were connected to the EEG apparatus while in separate cages. EEG signals were recorded using CED 1902 amplifiers to display and record the EEG signals on a computer with spike2 software (Cambridge Electronic Design, LTD.). After~30 minutes of baseline EEG recording, the animals were pretreated with 2PAM (25 mg/kg, subcutaneously [SC] in PND21 and 28, intramuscular [IM] in PND70) 20 minutes before agent exposure. The animals were exposed SC (PND21 and PND28, 0.15-0.25 mL; PND70, 0.30-0.45 mL) to SEinducing doses of the nerve agents sarin (PND21, 120 μg/ kg; PND28 and PND70, 190 μg/kg) or VX (PND21 and PND28, 40 μg/kg; PND70, 36 μg/kg). These challenge doses were taken from a previous study 22 and take into account the differences in toxicity of these agents across developmental ages of rats. 26 Animals administered sarin received an admixture of atropine sulfate (ATSO 4 ; 0.5 mg/ kg) and methyl atropine nitrate (AMN; 2 mg/kg) directly after agent exposure; animals given VX received the admixture at first signs of toxicity. For PND21 and PND28 rats, all injections (including agent) were SC; PND70 rats also received agent SC but received 2PAM, ATSO 4 , and AMN IM due to the larger muscle mass in the adult animals. These treatments significantly reduced the early lethal effects of the 2 nerve agents without preventing the development of SE. Five minutes after seizure onset as confirmed on EEG, animals were treated interperitoneally (IP) with SPD, VCD, or phenobarbital. SPD and VCD were prepared in a solution of propylene glycol, alcohol, and water for injection at a ratio of 6:2:2; phenobarbital was diluted from its parent commercial solution to 32.5 mg/mL with sterile saline. The up-down method was used over successive testing sessions to determine the anticonvulsant ED 50 of each of the three drugs. In the up-down method, 27 an initial testing dose is chosen, usually based on previous work, and then a succession of doses in 0. 27 To be rated as having 
| Statistics
An ad hoc analysis was conducted on the log(10) of the ED 50 values to compare those values among drug groups, PND age groups, agents, and sexes. The log(10) of the ED 50 values was used in the analysis to reduce the variability of the data. A 4-factor analysis of variance (ANOVA) was used with all 2-factor interactions. All 2-factor interactions were not significant; therefore they were removed from further analysis. A 4-factor ANOVA with only main effects was conducted, followed by a Tukey's multiple comparison on ages and drugs if the main effect was significant. Seizure termination latencies were grouped according to the challenge nerve agent and treatment drug and then compared within an age group with Kruskal-Wallis test followed by a Dunn post hoc test to determine differences between drug groups and age groups. No attempt was made to further distinguish if there were differences between the sexes on this measure due to the low and variable numbers of female and male animals within the different age and drug groups. In all statistical tests, P < 0.05 was considered statistically significant.
| RESULTS
The results of these experiments are shown Table 1 , which presents the anticonvulsant ED 50 values and their 95% confidence intervals for each drug as a function of sex, age group, and challenge nerve agent. The statistical analysis showed a significant effect of age (P < 0.0001), a small but significant effect of sex (P = 0.0425), and a slight, but not significant effect of drug (P = 0.0627). There was no significant effect of agents. The ED 50 values for PND21 were significantly lower than those for both the PND28 and PND70 age groups, (P < 0.05). Overall the ED 50 for male rats was slightly but significantly greater than the ED 50 for female rats (P = 0.0425). Although not statistically significant, treatments showed a minor difference in ED 50 values with higher amounts of VCD being required for an anticonvulsant effect, followed by SPD and phenobarbital.
Anticonvulsant dose estimates could not be reliably determined for phenobarbital in PND70 animals in the VX model or sarin model (male rats only) because the test doses of phenobarbital resulted in rapid toxicity. Figure 3 displays seizure termination latencies for each age group, challenge agent, and treatment drug. There were no significant differences between treatments in the PND21 age group in the time to terminate seizures. However, PND28 animals that were challenged with sarin and treated with phenobarbital had significantly longer seizure termination latencies than VX-challenged animals treated with phenobarbital which, in turn, had significantly longer latencies F I G U R E 2 A, Example of anticonvulsant EEG response of a male PND21 rat exposed to sarin and treated 5 minutes after seizure onset with 42 mg/kg SPD (IP). 1. Baseline EEG prior to sarin exposure. 2. Seizure onset~7 minutes after sarin challenge; note repetitive spiking that progressively increases in amplitude. 3. Seizure activity at the time of SPD treatment. 4. EEG 15 minutes after SPD treatment; EEG remained seizure-free throughout the remainder of the recording session of~4 hours. B, Example of anticonvulsant response of a female PND28 rat exposed to VX and treated 5 minutes after seizure onset with 56 mg/kg VCD (IP). 1. Baseline EEG prior to VX. 2. Seizure onset~19 minutes after VX challenge; note repetitive spiking that progressively increases in amplitude; VX-induced seizure were always substantially delayed compared to sarin. 23,31 3 . EEG activity at time of VCD treatment. 4. EEG 22 minutes after VCD treatment; EEG remained seizure-free throughout the remainder of the recording session of~4 hours than VX-challenged animals treated with VCD. In the PND70 age group, VX-challenged animals treated with phenobarbital had significantly longer seizure termination latencies than VX-challenged animals treated with VCD. In both the immature and adult animals treated successfully with SPD or VCD, a small percentage (8 of 90; 9%) developed sporadic episodes of seizure activity 2-3 hours after successful initial treatment. These developed as short (5-15 seconds) episodes of spikes separated by periods of normal EEG. As time went on, the duration of these episodes increased and became more frequent. The incidence of seizure reoccurrence was more frequent in SPD-treated animals (6 of 50; 12%) than in VCD-treated subjects (2 of 40; 5%) and was distributed randomly across age groups, sexes, and challenge agents (SPD: 2 PND21 males challenged with sarin, 1 PND21 female challenged with VX; 1 PND28 male challenged with VX; 2 PND70 males challenged with sarin; VCD: 1 PND21 male challenged with sarin; 1 PND28 female challenged with VX). This mostly occurred in animals treated with lower doses of these 2 compounds. A reoccurrence of seizure activity was not seen with phenobarbital.
| DISCUSSION
The results show that SPD, VCD, and phenobarbital are capable of terminating SE seizures induced by the nerve agents VX or sarin in both immature and adult rats of both sexes, but with a number of important caveats. Overall, The 95% confidence interval (95% CI) around the ED 50 value.
d ND, ED 50 could not be determined due to early toxicity (maximum dose tested).
F I G U R E 3
Seizure termination latencies for each treatment drug as a function of age group and nerve agent challenge. Data are presented as box-and-whiskers plots; bar within the box represents medians, edges of the box are 95% confidence limits, and bars outside the box are the minimum and maximum responders. Each symbol represents a successful anticonvulsant response; both male and female animals are represented in each condition there was a trend for ED 50 doses of all 3 treatments to increase with age, with the most notable differences being between the PND21 age group and the older animals. In addition, overall, compared to female animals, male animals required higher ED 50 doses. Although not statistically significant, there was a trend that animals treated with VCD required higher drug doses to achieve an anticonvulsant effect compared to SPD or phenobarbital. Furthermore, there was no differential effect of these drugs for treating SE initiated by the 2 different nerve agents, indicating a common neuropharmacologic mechanism by which these toxic compounds initiate and maintain these seizures. 21, 23 The reason for the marked differences in the effectiveness of these drugs across developmental ages is most probably linked to body weight changes coupled with developmental differences in the drugs' pharmacokinetics. There was an approximate 90% increase in body weight over 1 week between PND21 (female = 47.1 g; male = 52.8 g) and PND28 (female = 88.3 g; male = 98.1 g) animals, the 2 developmental ages that differed the most. In contrast, the change in weights between PND28 and PND70 (female = 266.4 g; male = 437.4 g) animals is 302% and 446%, respectively, over 6 weeks. The greater proportional weight gain in male rats over this period could also contribute to the finding that, overall, male rats required higher drug amounts than females did.
Previous work has shown that both VCD and SPD were capable of controlling SE induced by the nerve agent soman in adult male rats and guinea pigs. 7, [12] [13] [14] The present results extend those findings to SE seizures induced by 2 other nerve agents, VX and sarin, in both immature and adult male and female rats. In the previous studies, both VCD and SPD were given at substantially longer delay times (20 minutes, 40 minutes after seizure onset) and were given in conjunction with the benzodiazepine diazepam at a dose (2.2 mg/kg, IM) that was incapable of stopping SE on its own. Under those conditions, the ED 50 values for seizure control ranged from 67 to 92 mg/kg (SPD) and 62-80 mg/kg (VCD), which are comparable to the those for adult rats obtained in the present study, where these drugs were used at a shorter time following seizure onset and without the benefit of coadministration of a benzodiazepine. In a previous study utilizing the pentylenetetrazol-induced seizures in immature rats, VCD, 2 of its stereoisomers (2S,3S)-VCD and (2R,3S)-VCD, and VCD-constitutional isomer propylisopropylacetamide (PID) exhibited anticonvulsant activity in all 4 age groups studied. 28 VCD (racemate) was more potent than its constitutional isomer PID against generalized tonic-clonic seizures (GTCS) and generalized seizures without tonic phase (GCS) in the PND18 and PND25 age groups. However, no differences were found between these 2 constitutional isomers in the PND7 and PND12 age groups. The 2 tested VCD stereoisomers had similar ED 50 values that did not differ significantly from that of racemic-VCD. All 4 tested drugs were more potent than VPA. VPA doses of 50-400 mg/kg (IP) were used in a previous study, and only VPA doses of 150 mg/kg or higher suppressed GTCS in all age groups of immature rats. 29 All of these studies confirm previous reports showing that VPA has the weakest ED 50 values among the antiepileptic agents in various anticonvulsant animal (rodent) models. 30 In the present study, SPD, VCD, and phenobarbital demonstrated good anticonvulsant activity in 2 new nerve agent models of SE in both adult (PND70) and immature (PND21, PND28) rats of both sexes. To date, SPD and VCD have shown anticonvulsant activity in multiple other rat-SE models (pilocarpine, soman, paraoxon, and tetramethylenedisulfotetramine), demonstrating the broad anti-SE spectrums of these 2 homologous CNS-active compounds. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] There is an ongoing need to identify new drugs to treat SE, whether induced by nerve agents or of other etiologies. The present data show that SPD, VCD, and to a lesser extent phenobarbital, are effective in both sexes across all age groups.
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